Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
- 675 Downloads
Background and Objectives
Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ9-tetrahydrocannabinol (THC) for chronic PTSD.
Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ9-THC twice a day as add-on treatment.
There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.
Orally absorbable Δ9-THC was safe and well tolerated by patients with chronic PTSD.
Raphael Mechoulam has consulted to GW Pharmaceuticals, UK.
- 13.Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):6.Google Scholar
- 15.Guy GW. The Clinical Global Impression Scale. In: ECDEU assessment manual for psychopharmacology–revised. Bethesda; US Department of Health, Education and Welfare; 1976: pp 218–222.Google Scholar
- 19.Guy GW. A phase 1, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther 2003;3:31.Google Scholar
- 22.Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt Int. 2012;109(29–30):495–501.Google Scholar